GlassScriptPhysician profile
Sumit Na Anand
NPI 1902838899
$495.28
in general payments reported to CMS, 2019-2025
12 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2021: $62.82 · 2023: $109 · 2024: $48.55 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $119.81 | 2019-2021 | |
| Corium, LLC | $61.29 | 2024-2025 | Azstarys |
| Alkermes, INC. | $60.67 | 2019-2023 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $55.23 | 2023-2025 | Nuedexta, Rexulti |
| Tris Pharma INC | $44.68 | 2023-2024 | Dyanavel Xr |
| Bausch Health US, LLC | $41.98 | 2025 | Aplenzin |
| Allergan, INC. | $20.39 | 2019 | |
| Neuronetics, INC. | $20.29 | 2025 | Neurostar Tms Therapy System |
| Lundbeck LLC | $19.60 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $17.46 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $17.03 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $16.85 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.